MultiVu Video Feed: Endo Receives FDA Approval for Extended-Release and Immediate-Release OPANA(R) Tablets (Oxymorphone HCl) CII
Posted on: Friday, 23 June 2006, 12:00 CDT
NEW YORK, June 23 /PRNewswire/ -- Chronic Pain is a Public Health Issue. It's estimated that pain costs the U.S. more than $100 billion annually in healthcare expenditures and lost productivity. In fact, research shows pain contributes to more than 50 million lost workdays each year. Although data suggest that pain is often undertreated, experts agree that chronic pain patients need around-the-clock coverage with an analgesic agent to sustain pain relief
Chronic Pain Patients Need New Treatment Options. As the population ages, the number of people who will need treatment for pain -- from back disorders, degenerative joint disease, visceral diseases, and cancer -- is expected to rise. Approximately 10% of Americans suffer from moderate-to-severe chronic pain. Additionally, physicians often need to rotate opioids in order to effectively manage a patient's chronic pain because patients can develop tolerance to a particular treatment.
* OPANA(R) ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid therapy for an extended period of time and is not intended to be used on an as-needed basis. * OPANA(R) is indicated for the relief of moderate-to-severe pain where the use of an opioid is appropriate. * The clinical program for Opana(R) ER and Opana(R) represents one of the most comprehensive ever conducted for an opioid analgesic. SATELLITE FEEDS: Friday June 23rd, 2006 Friday June 23rd, 2006 10:30 AM - 10:45 AM ET 2:00 PM - 2:15 PM ET IA 6 IA 6 Transponder 15 Transponder 16 C-Band C-Band Downlink Freq: 4000 Vertical Downlink Freq: 4020 Horizontal Preview and access this video on Pathfire DMG: 24447 Search within the PR Newswire or MultiVu section by story ID # 24447 or by headline For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com
NEWS: Opana(R) and Opana(R) ER Tablets Receive FDA Approval for the Treatment of Moderate-to-Severe Pain
FORMAT: B-Roll with Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at http://www.prnewswire.com/broadcast/24447/consumer.shtml
SOUNDBITES:
Richard Rauck, M.D., Clinical Associate Professor in the Department of Anesthesiology at Wake Forest University School of Medicine
Peter A. Lankau, President and CEO, Endo Pharmaceuticals Inc. B-ROLL INCLUDES: ***Doctor/Patient B-roll***Corporate Headquarters*** VIDEO PROVIDED BY: Endo Pharmaceuticals Inc.
Video: http://www.prnewswire.com/broadcast/24447/press.shtml
Endo Pharmaceuticals Inc.
CONTACT: For Technical Information Or Hard Copy, Please Call:MultiVu Media Relations, 800-653-5313 EXT. 3
Web site: http://www.multivu.com/
Source: PRNewswire
Related Articles
- Video May Help Patients Make End-Of-Life Decisions
- Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
- BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
- New Hill-Rom Stretchers Address Patient and Caregiver Needs
- Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients With Treatment-Resistant Forms of Advanced Leukemias
- Study Published in Journal of Clinical Psychiatry Shows Long-Term Treatment- As-Usual Is Ineffective for Patients With Treatment-Resistant Depression
- Two-Year Data Showing Decreases in Suicidality in Patients With Treatment- Resistant Depression Treated With VNS Therapy Presented at Annual American Psychiatric Association Meeting
- First of Its Kind Study Shows Complimentary Alternative Medicine Reduces Pain and Tension in Heart Surgery Patients
- Savient's Puricase(R) (PEG-Uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients With Treatment-Resistant Gout
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
 |
 |
User Comments (0)
RSS Feeds